All Clinical Trials

Clinical Trial NCT02582697

AGCT1532, A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors

  • ClinicalTrials.gov ID: NCT02582697
  • Recruiting participants (Starts Sep. 4, 2018)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: JONATHAN ERIC WICKISER

summary

This trial is an open label, randomized, stratified 2-arm australian-led multicenter phase 3 clinical trial undertaken in two stages. Participants will be randomized via a central system administered by the australian nHMRC Clinical Trials Centre into either a "standard BeP" group or "accelerated BeP" group. Participants will be assigned to the two treatment arms in a 1:1 ratio and evaluated weekly, and then for 5 years after completing the study to assess the long-term effects of the chemotherapy.

objective

To determine if accelerated BeP (Bleomycin, etoposide, cisPlatin) is superior to standard BeP as first-line chemotherapy for intermediate and poor-risk metastatic GCTs

If you are interested in this clinical trial, please contact AMANDA RICHARDS on the Children’s Health Research Team.Call 214-456-6300Email